Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling-Reference-Cited by-同舟云学术

Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling

Published:2019-07 Issue:7 Volume:40 Page:250-261
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm Drug Dispos

Author:

Kimura Koji¹^ORCID,Yoshida Atsushi²,Katagiri Fumihiko¹,Takayanagi Risa¹,Yamada Yasuhiko¹

Affiliation:

1. Department of Clinical Evaluation of Drug Efficacy; School of Pharmacy, Tokyo University of Pharmacy and Life Sciences; 1432-1 Horinouchi Hachioji Tokyo 192-0392 Japan

2. Center for Gastroenterology and Inflammatory Bowel Disease; Ofuna Chuo Hospital; 6-2-24 Ofuna Kamakura Kanagawa 247-0056 Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/bdd.2198/fullpdf

Reference47 articles.

1. Inflammatory bowel disease;Abraham;The New England Journal of Medicine,2009

2. Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases;Avdagic;Medicinski Glasnik,2013

3. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study;Best;Gastroenterology,1976

4. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease;Billiet;Scandinavian Journal of Gastroenterology,2017

5. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease;Candon;Clinical Immunology,2006

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review;Pharmaceutics;2022-09-30

2. Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study;European Journal of Gastroenterology & Hepatology;2022-03-29

3. Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model;Pharmaceutics;2021-11-01

4. Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model;Clinical Pharmacokinetics;2021-08-05

5. Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling;European Journal of Pharmaceutical Sciences;2020-07